Shares of Diplomat Pharmacy Inc (NYSE:DPLO) have been given a consensus rating of “Hold” by the fourteen ratings firms that are covering the company, Marketbeat reports. Eight equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $25.15.
A number of research firms have recently weighed in on DPLO. Deutsche Bank upgraded shares of Diplomat Pharmacy from a “hold” rating to a “buy” rating in a report on Friday, March 2nd. Zacks Investment Research cut shares of Diplomat Pharmacy from a “buy” rating to a “hold” rating in a report on Wednesday, February 21st. Barclays began coverage on shares of Diplomat Pharmacy in a report on Thursday, March 8th. They issued an “overweight” rating and a $27.00 price target on the stock. Needham & Company LLC set a $28.00 price target on shares of Diplomat Pharmacy and gave the company a “buy” rating in a report on Tuesday, February 27th. Finally, Leerink Swann upgraded shares of Diplomat Pharmacy from a “market perform” rating to an “outperform” rating and set a $23.00 price target on the stock in a report on Monday, December 11th.
In related news, Director Philip R. Hagerman sold 2,150,000 shares of Diplomat Pharmacy stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $20.65, for a total value of $44,397,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 30.20% of the stock is owned by company insiders.
Shares of DPLO stock traded down $1.00 during trading on Wednesday, reaching $20.28. 800,654 shares of the company’s stock traded hands, compared to its average volume of 1,121,000. The company has a current ratio of 0.97, a quick ratio of 0.66 and a debt-to-equity ratio of 0.70. Diplomat Pharmacy has a one year low of $14.00 and a one year high of $27.78. The company has a market cap of $1,576.19, a PE ratio of 96.57 and a beta of 1.32.
Diplomat Pharmacy (NYSE:DPLO) last issued its earnings results on Monday, February 26th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.16 by $0.02. Diplomat Pharmacy had a net margin of 0.35% and a return on equity of 8.89%. The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the prior year, the business earned $0.08 EPS. The firm’s quarterly revenue was up .9% on a year-over-year basis. research analysts predict that Diplomat Pharmacy will post 0.94 earnings per share for the current year.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.